← Back to patent-cliff list
Gefapixant Citrate
Tier C — Watch / tradeGefapixant Citrate
F. Hoffmann-La Roche
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：P2RX3
Brand：Lyfnua
Indications (approved)：Cough
Regional status
US
Phase III
2018-03-14
EU
Approved
2023-09-15
China
Phase III
2018-03-15
Japan
Approved
2022-01-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Gefapixant Citrate?
Approved indications include: Cough.
When does the Gefapixant Citrate patent expire?
No public expiry year is available for Gefapixant Citrate yet; this page updates once verified.
How do I get a quote for Gefapixant Citrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27